1717 K Street NW, Suite 900

Washington, DC 20006-5349

(877) 363-6376

HELPLINE

NEWS

MesoTV: Dr. R. Taylor Ripley of Baylor College of Medicine

Baylor College of Medicine mesothelioma program

Dr. R. Taylor Ripley discusses his research interests, diet and cancer, as well as seeking care and the mesothelioma program at Baylor College of Medicine during COVID-19:

  • Telemedicine: Available via Epic.
  • Surgery: Available on a case-by-case basis.
  • Clinical trial: Open & enrolling with PI Dr. Bryan Burt.

Dr. Ripley is a thoracic surgeon, director of the Mesothelioma Treatment Center at Baylor College of Medicine and member of the Foundation’s Board of Directors.

“I want to encourage patients to seek help. I know there are patients who feel like they are stuck at home because of the pandemic, but, fortunately, with cell phones, computers and Zoom technology, we have a lot of ways to interact with patients so please reach out.”

Dr. R. Taylor Ripley

Watch MesoTV

This MesoTV interview was made possible by the support of sponsors who have stepped up during this difficult time to ensure that we can continue serving the mesothelioma community. Please take note of them at the beginning of the video: Novocure; Belluck & Fox, LLP; University of Pittsburgh Medical Center (UPMC); Vogelzang Law; and Merrill Lynch.

Get notified when our next video is published by clicking the red “Subscribe” button below.

MesoTV is the Mesothelioma Applied Research Foundation’s recorded video series covering pertinent conversations impacting the mesothelioma community. You can learn more at curemeso.org/mesotv.

Also...

In Other News

Clinical Trials

Mesothelioma is one of the rarest cancers so there are always clinical trials going on to advance research efforts. This session presents on four different

Read More »

Peritoneal Surgery/HIPEC

Peritoneal mesothelioma patients have a few different treatment options available. This session discusses two options: surgery as well as hyperthermic intraperitoneal chemotherapy (HIPEC).  This session

Read More »

Share:

Facebook
Twitter
LinkedIn